FDA Greenlights Cancer Breakthroughs While Heart Drug Failures Shake Pharma

The FDA has approved two new cancer drugs in the past 24 hours, offering fresh hope for patients with hard-to-treat malignancies, even as the industry reels from high-profile cardiovascular trial failures.

Vital Signs

• 16 months: Median progression-free survival for breast cancer patients on the new drug Etcamah, compared to 9.2 months on standard therapy
• Nearly doubled survival: In a pancreatic cancer trial, the new pill daraxonrasib showed a dramatic...